Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CT | 0.800 | CausalMutation | CLINVAR | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. | 22805292 | 2012 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. | 22805292 | 2012 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. | 22972589 | 2013 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. | 22972589 | 2013 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. | 23020132 | 2012 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. | 22735384 | 2012 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. | 22735384 | 2012 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | 22608338 | 2012 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | 22608338 | 2012 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. | 25656898 | 2015 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Determinants of BRAF mutations in primary melanomas. | 14679157 | 2003 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Determinants of BRAF mutations in primary melanomas. | 14679157 | 2003 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. | 23317446 | 2013 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Improved survival with MEK inhibition in BRAF-mutated melanoma. | 22663011 | 2012 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Improved survival with MEK inhibition in BRAF-mutated melanoma. | 22663011 | 2012 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | 21639808 | 2011 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | 21639808 | 2011 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. | 20630094 | 2010 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Inhibition of mutated, activated BRAF in metastatic melanoma. | 20818844 | 2010 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Inhibition of mutated, activated BRAF in metastatic melanoma. | 20818844 | 2010 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Mutations of the BRAF gene in human cancer. | 12068308 | 2002 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. | 23248257 | 2013 |
|||||||
|
|
TT | 0.800 | CausalMutation | CLINVAR | Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. | 23918947 | 2013 |
|||||||
|
|
CT | 0.800 | CausalMutation | CLINVAR | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. | 22048237 | 2012 |